Nano‐optogenetic immunotherapy
Chimeric antigen receptor (CAR) T cell‐based immunotherapy has been increasingly used in the clinic for cancer intervention over the past 5 years. CAR T‐cell therapy takes advantage of genetically‐modified T cells to express synthetic CAR molecules on the cell surface. To date, up to six CAR T cell...
Main Authors: | Kai Huang, Xiaoxuan Liu, Gang Han, Yubin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-09-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ctm2.1020 |
Similar Items
-
Optogenetic Control of Non‐Apoptotic Cell Death
by: Lian He, et al.
Published: (2021-07-01) -
Surface-enhanced FAST CARS: en route to quantum nano-biophotonics
by: Voronine Dmitri V., et al.
Published: (2018-02-01) -
Harnessing natural killer cells to develop next‐generation cellular immunotherapy
by: Siyao Liu, et al.
Published: (2022-12-01) -
Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights
by: Zuhui Pu, et al.
Published: (2023-11-01) -
Energetic homeostasis achieved through biophoton energy and accompanying medication treatment resulted in sustained levels of Thyroiditis-Hashimoto's, iron, vitamin D & vitamin B12
by: Mariola A. Smotrys, et al.
Published: (2023-06-01)